- recruitingPHASE3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
United States · Australia · Austria - active not recruitingPHASE3
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to previous platinum-based chemotherapy. It looks at how well adding a drug called relacorilant to nab-paclitaxel works compared to nab-paclitaxel alone.
United States · Argentina · Australia